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Lidocaine unmasks silent symptoms and eases neuropathic pain in multiple sclerosis patients; however, the eﬀects of lidocaine in
neuromyelitis optica have never been reported. We describe the case of a 59-year-old Japanese woman with neuromyelitis optica
spectrum disorder who developed optic neuritis 1 day after intravenous lidocaine injection for treating allodynia. Her symptom
seemed to result from a relapse of neuromyelitis optica induced by lidocaine administration, and not because of the transient
eﬀects of intravenous lidocaine administration. The possibility that lidocaine administration results in relapse of neuromyelitis
optica due to its immunomodulating eﬀects cannot be ruled out.
1.Introduction
Lidocaine has been reported to unmask silent symptoms,
such as paralysis, hypaesthesia, and visual loss; it has also
been shown to abolish painful tonic seizures, neuropathic
pain and dysaesthesia in multiple sclerosis (MS) [1]. How-
ever, the eﬀects of intravenous lidocaine in neuromyelitis
optica (NMO) have never been reported. NMO is an
immune-mediated inﬂammatory disorder of the central
nervous system that predominantly aﬀects the optic nerves
and spinal cord [2]. Since the discovery of the anti-
aquaporin-4 antibody in the sera of patients with NMO [3],
several reports have described diﬀerences in the pathology
[4], immunological status [5], and response to interferon-
beta [6] between MS and NMO, indicating that NMO and
MS are diﬀerent diseases. We describe a patient with NMO
spectrum disorder who presented with optic neuritis after
administration of intravenous lidocaine.
2.CaseReport
A 59-year-old Japanese woman experienced inﬂammatory
episodes with a T1-2 thoracic spinal lesion and a T6-7
thoracic spinal lesion with numbness below the precordia at
the age of 57, and a C4-5 cervical spinal lesion and brainstem
lesion with diplopia, gait disturbance, and hypalgesia of
the right side at age 58. The patients was diagnosed as
NMO spectrum disorder because her serum anti-aquaporin-
4 antibody titre was positive but not completely fulﬁlling
Wingerchuk’s criteria for NMO [2]. The patient suﬀered
from allodynia presenting at the right T2-4 dermatomal
area due to a previous thoracic spinal cord lesion and
visited an anaesthesiologist. She was then treated with
intravenous lidocaine (100mg) followed by oral mexiletine
(150mg/day) for allodynia. The next day she began to lose
left visual acuity, and it gradually worsened. Oral mexiletine
was stopped 3 days after treatment began. She consulted
us 5 days after she had noted the loss of visual acuity.
Neurological examination revealed visual loss in the left
eye (visual acuity less than 20/200), and allodynia and
hyperalgesia in the right T2-4 dermatomal area. A titre
of the anti-aquaporin-4 antibody at that time was higher
than that measured 2 and 6 months prior, and lidocaine
concentration was below the detection limit (<0.9pg/mL)
in her serum. Brain magnetic resonance images with
gadolinium enhancement taken 7 days after the onset of
symptom revealed a new left optic nerve lesion (Figure 1).
She was diagnosed with optic neuritis and treated with
intravenous methylprednisolone (1g/day) for 3 days and
four additional applications of immunoadsorptive plasma-
pheresis. Her visual loss was completely resolved within a
month.2 Case Reports in Medicine
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Figure 1: Brain magnetic resonance images with T1-weighted gadolinium enhancement performed 1 week after the onset of left visual loss.
A high-intensity lesion on the left optic nerve is seen (white arrows).
3. Discussion
We suspected that the patient’s visual loss occurred due to
a relapse of NMO, which is presumed to be induced by
lidocaine administration. However, the transient eﬀects of
intravenous lidocaine administration were ruled out since
the patient’s visual loss persisted even when her serum
lidocaine concentration was below the detection limit and
brain magnetic resonance images revealed a new optic nerve
lesion. To the best of our knowledge, no studies have
reported the relapse of a demyelinating disease that was
induced by lidocaine administration. Lidocaine is a sodium
channel blocker that unmasks silent symptoms and abolishes
neuropathic pain, and dysaesthesia in patients with MS [1],
presumably by reducing the size of the action potentials
and safety factors for impulse transmission at demyelinated
portions of neurons, resulting in the blocking or slowing
of nerve conduction [7]. However, the eﬀects of lidocaine
are usually only apparent during its administration and
are reversible [1] due to the drug’s short half-life. We
hold some speculations about the association between the
administration of lidocaine and relapse of NMO in this case
as follows.
Firstly,lidocaineregulatedtheimmunologicalconditions
of NMO. Some studies have reported that sodium channel
blockers can regulate immunological responses, such as
promoting Th2-type immune responses [8, 9]. Recently,
we had reported that the signiﬁcant upregulation of Th2-
and Th17-related cytokines/chemokines in the cerebrospinal
ﬂuid of NMO patients, but not MS patients [5]. In our
case,intravenouslidocainemayhavemodulatedtheimmune
system, leading to aggravation of the NMO condition.
Secondly, lidocaine blocked neural conduction in the
unrecognized demyelinated or inﬂamed sections of neurons
in NMO. Lidocaine has been shown to cause irreversible
conduction block in vitro [10]. In addition, inﬂammation
causes a decline in the safety factors of conduction. The
release of nitric oxide at sites of inﬂammation is associated
with an axonal conduction block; demyelinated axons are
particularly sensitive [11]. However, we believed that con-
duction blocks alone cannot explain the patient’s condition
because her condition did not worsen immediately after the
administration of lidocaine and gadolinium-enhanced brain
magneticresonanceimagesrevealedanewopticnervelesion.
There are some possible explanations for this case. We
cannot deny association between the relapse and administra-
tion of intravenous lidocaine was coincidental, but it may be
suggested that lidocaine administration led to changes in the
patient’simmunologicalconditionandresultedintherelapse
of NMO. Physicians should recognise that such conditions
may occur in patients diagnosed with NMO.
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